The previous studies of our group demonstrated synthetically lethal interaction between a PARP inhibitor (BMN) and class I histone deacetylases, as well as PARPi and LIG4 deficiency in glioblastoma cells [30,31]. This evidence concerns the gene PARP1 and glioblastoma.